news details |
|
|
| Drug Quality Assurance | | |
In a startling revelation, our country’s central drug regulatory authority has identified over 50 commonly used medications—including paracetamol, Pan D, various calcium and vitamin D3 supplements, and crucial anti-diabetes pills—as “not of standard quality” in its latest report. This finding raises significant concerns not only about public health but also about the integrity of our healthcare system.
The implications of substandard drugs cannot be overstated. Medications such as Telmisartan, used to manage high blood pressure, and Amoxicillin, a widely prescribed antibiotic, are vital for countless patients. When these medications fail to meet quality standards, the consequences can be dire, ranging from ineffective treatment to serious health risks. Patients relying on these drugs to manage chronic conditions or recover from infections are left vulnerable, potentially facing deteriorating health or, in extreme cases, life-threatening situations.
The drug regulator assures the public that it constantly monitors the quality of medications through monthly random testing. While this practice is commendable, the recent findings indicate a systemic failure in ensuring the efficacy and safety of pharmaceuticals in circulation. The sheer number of drugs flagged as substandard raises urgent questions about the robustness of our quality control measures. Are these random tests sufficiently rigorous? How are manufacturing firms held accountable for lapses in quality?
It is crucial to consider the larger context in which these drugs are produced. A significant portion of our pharmaceutical supply chain relies on manufacturing practices that may prioritize profit over patient safety. In an era where the global market for pharmaceuticals is intensely competitive, some manufacturers may cut corners, leading to compromised quality. Regulatory authorities must ramp up inspections and enforce stricter compliance to ensure that the standards set forth are not only theoretical but also actively upheld.
Furthermore, transparency is essential. The public has a right to know about the quality of the medications they consume. Increased disclosure of testing results and the names of manufacturers who produce substandard products could empower consumers to make informed decisions about their health. Additionally, providing clear guidance on how to report adverse effects or suspected quality issues could enhance patient safety and foster greater accountability among manufacturers.
There is also an urgent need for collaboration between regulatory authorities and healthcare professionals. Doctors and pharmacists play a pivotal role in monitoring the efficacy of medications and can provide invaluable feedback on the quality of drugs in the market. Establishing clear channels for communication between these stakeholders could lead to earlier detection of quality issues and a more responsive regulatory environment. |
|
|
|
|
|
|
|
|
|
|
|
|
| |
| |
|
|
|
|
 |
|
|
|
|
STOCK UPDATE |
|
|
 |
| BSE
Sensex |
 |
| NSE
Nifty |
|
|
| |
CRICKET UPDATE |
|
|
|
|
| |
| |
|
|
| |
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
